What HBVax PRO Treats: Main Uses and Benefits

HBVax PRO is commonly used for active immunisation to prevent the Hepatitis B virus infection from developing into a chronic state. This prevention supports the reduction of long-term health risks associated with chronic HBV, including the development of severe liver conditions like cirrhosis and the risk of primary hepatocellular carcinoma (liver cancer).

The preventative benefit applies to establishing lasting protection against infection by all known subtypes of the virus, averting the acute symptomatic phase, and assisting with the prevention of co-infection with the Hepatitis D virus. The vaccine is commonly applied in clinical settings for universal infant vaccination, for adults and adolescents facing a heightened risk of exposure such as healthcare and public safety personnel, and for specific patient categories like predialysis and dialysis patients. This broad use contributes to easing the overall symptom load across both general and susceptible populations.

---

Quick Fact: Focus on Prevention of Severe Disease Risk

The vaccine is considered relevant across therapeutic domains focused on preventative hepatology and preventative oncology, and may assist in reducing the risk of severe, long-term complications linked to chronic HBV infection.

Regulatory References

1. European Medicines Agency summary for HBVaxPro

Who can and cannot use HBVax PRO?

This information describes the official population eligibility rules for HBVax PRO as documented in government regulatory sources.

Contraindications and Restrictions

HBVax PRO is contraindicated for individuals with a known history of hypersensitivity to the active substance (Hepatitis B virus surface antigen) or to any of the vaccine's excipients or trace residuals. Individuals with a severe febrile illness or acute infection must postpone vaccination until the condition resolves.

Age-Specific Eligibility

The appropriate formulation is determined by age:

Formulation Strength	Eligible Age Group
5 micrograms	Individuals from birth through 15 years of age
10 micrograms	Individuals 16 years of age or more

Special Populations

Caution should be exercised when prescribing the vaccine to pregnant or breast-feeding women, and use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. Dialysis patients and predialysis adults are eligible for a specific high-dose (40 microgram) formulation. Patients with bleeding disorders are eligible, though the administration route may need to be adjusted.

Interactions with other medicines and products

Official regulatory documents detail the required procedural constraints when HBVax PRO is administered with other products, rather than classical drug-drug interactions affecting metabolism or transport.

Interaction Type/Product
Hepatitis B Immunoglobulin	Can be given concurrently but must be administered at a separate injection site.
Other Vaccines	May be administered at the same time but must use separate sites and syringes.
Mixing Constraint	Must not be mixed in the same syringe with any other medicinal products, due to the absence of compatibility studies.
Previous Vaccination	Can be used to complete a primary vaccination course or as a booster dose in individuals who have previously received another licensed hepatitis B vaccine.
Limited Study Data	Concomitant administration with certain specific vaccines, such as Pneumococcal Conjugate Vaccine (PREVENAR) using particular official schedules (e.g., the 0, 1, 6 or 0, 1, 2, 12 month schedules), has not been sufficiently studied.

These official statements define the necessary co-administration logistics, ensuring the integrity and expected efficacy of the vaccine are maintained. The interaction profile is therefore governed by specific rules for product handling and administration timing rather than physiological drug-drug effects.

HBVax PRO functions as an exogenous antigen, consisting of the Hepatitis B surface antigen (HBsAg) protein. Following systemic administration, the HBsAg component is internalized by Antigen-Presenting Cells (APCs), primarily dendritic cells and macrophages, via endocytosis. Within the APCs, the HBsAg is processed into short peptide fragments. These fragments are then loaded onto Major Histocompatibility Complex (MHC) Class II molecules and displayed on the APC cell surface.

This presentation initiates the cell-mediated immune cascade. Specifically, the displayed MHC Class II/peptide complex interacts with the T-cell receptor (TCR) of cognate CD4+ helper T lymphocytes. This binding event, coupled with co-stimulatory signals, drives the activation and clonal expansion of the CD4+ T-cell population. Activated CD4+ T cells subsequently release cytokines, which act as signals to promote the maturation and differentiation of B lymphocytes specific for HBsAg epitopes.

B-cell differentiation culminates in the production of plasma cells and memory B cells. Plasma cells are the primary effectors, engaging in the robust, systemic secretion of anti-HBsAg antibodies into the circulation. These antibodies represent the molecular consequence of the pathway, providing system-level humoral modulation of the host's immunological profile.

How to Use HBVax PRO: Administration Guidelines

This section describes the usage instructions for the HBVAXPRO Hepatitis B vaccine.

---

Administration and Dosing

Route of Administration:

HBVAXPRO is administered via intramuscular (IM) injection. The preferred injection site is the deltoid muscle in the upper arm for children, adolescents, and adults. For neonates and infants, the anterolateral aspect of the thigh is the recommended site. Subcutaneous injection may be used in individuals with a bleeding disorder or severe thrombocytopenia.

Standard Dosing Strengths:

The required dose volume and strength depend on the recipient's age and health status:

Population	Single Dose Strength	Volume
Infants, Children (Birth through 15 years)	5 micrograms	0.5 mL
Adolescents, Adults (16 years and older)	10 micrograms	1.0 mL
Adult Dialysis/Predialysis Patients	40 micrograms	1.0 mL

---

Vaccination Schedules and Handling

Standard Primary Schedule:

The most common primary vaccination course consists of three doses administered according to a 0, 1, 6 months schedule (initial dose, one month after the first dose, and six months after the first dose). An accelerated 4-dose schedule (0, 1, 2, and 12 months) is also available for specific populations.

Preparation:

Before administration, the vaccine must be well shaken to obtain a slightly opaque white suspension. The product should be visually inspected for any abnormal appearance before use.

Missed Doses:

If the vaccination schedule is interrupted, the remaining doses are administered to complete the schedule, and there is no requirement to restart the course.

Research evidence on Primary Immunization with HBVax PRO

Outcomes in Healthy Adult Populations

Research was studied for patterns observed in the systemic status of healthy adults. These initial studies were conducted under observational settings evaluating daily-life functioning and studies observing responses over defined time intervals. Research primarily monitored outcomes reflecting daily functioning or activity level in participants following administration of the product.

The research describes the patterns observed in the measured outcomes regarding systemic status in the observed populations. These results contribute to understanding patterns observed in the study population. However, it is important to understand that the results apply only to the populations studied in these specific settings.

The long-term effects are not fully established, and certainty remains low regarding how patterns of change measured during the study period relate to longer-term systemic status. The follow-up durations were limited in many of the initial trials, meaning that data are still emerging for long-term outcomes reflecting daily functioning or activity level.

Research exploring short-term outcomes related to systemic or functional imbalance

Separate research was evaluated in settings focusing on research exploring short-term symptom changes following product administration. These were studies focusing on episodes where symptoms become more noticeable and research examined temporary physiological status in the period immediately after the product was given. The outcomes capturing phases of heightened symptom activity were monitored closely.

Research in Special Populations

Individuals with Conditions Characterized by Fluctuating Symptoms

HBVax PRO was evaluated in small-scale studies involving individuals with conditions characterized by fluctuating or episodic manifestations. The evidence is limited for these groups because the sample sizes were modest and the subgroup findings are uncertain. The research provides context but not individual predictions, as findings describe group patterns, not personal outcomes.

Key Studies & References

1. Phase 3 Trial of HBVax PRO for Primary Immunization: Systemic Status and Functional Outcomes in Healthy Adults

Common questions about HBVax PRO (FAQ)

---

Q: How is the HBVax PRO vaccine disposed of after use?

According to official product information, any unused vaccine or waste materials, including the vial after dose withdrawal, are not to be thrown away using household waste or wastewater. These items should be disposed of promptly and in accordance with local requirements. Guidance on disposal may be obtained by consulting a pharmacist.

---

Q: Can HBVax PRO be given at the same time as other vaccines for different diseases?

Official regulatory documents state that the HBVax PRO vaccine can generally be administered at the same time as other vaccines. The label specifies that the vaccine is not to be mixed with any other medicinal product in the same syringe. If co-administered, it is to be given at a separate injection site.

---

Q: Is the HBVax PRO vaccine safe for individuals who have a known latex allergy?

The product label includes a warning regarding the use of the vaccine in individuals sensitive to latex. This is because the vial stopper and/or the syringe plunger stopper contains dry natural latex rubber. This material has the potential to cause allergic reactions in susceptible individuals.

---

Q: What should I do if I missed the first dose of the HBVax PRO vaccine schedule?

If the vaccination course has not been started, the standard recommendation is to receive a full course. If the series is interrupted after the initial dose, official schedules suggest that the second dose should be given as soon as possible. The third dose is typically administered to complete the full recommended schedule.

---

Q: What is the difference between the 5 microgram and 10 microgram HBVax PRO formulations?

The difference between the formulations is based on the recipient's age. Official product information states that the 5 microgram formulation is intended for individuals from birth through 15 years of age. The 10 microgram formulation is for individuals 16 years of age or older.

How to Store and Dispose of HBVax PRO

HBVax PRO must be stored under specific conditions to maintain its potency. The vaccine must be kept in a refrigerator at a temperature between 2°C and 8°C. It is critical not to freeze the product, as freezing destroys the vaccine. To prevent degradation, keep the product in its original package to protect from light and ensure it is stored out of the sight and reach of children.

The shelf life is 3 years when stored correctly. Before administration, the vaccine should be well shaken and visually inspected; do not administer if discoloration or foreign particulate matter is present.

For disposal, the product must not be thrown away via wastewater or household waste. Any unused medicine or waste material must be disposed of in accordance with local requirements, typically by consulting a pharmacist.